Timber Pharmaceuticals Inc.
Quick facts
Phase 3 pipeline
- TMB-001 · Dermatology
TMB-001 is a topical antifungal agent designed to treat fungal skin infections by disrupting fungal cell membrane integrity.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Timber Pharmaceuticals Inc.
What is Timber Pharmaceuticals Inc.'s pipeline?
Timber Pharmaceuticals Inc. has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include TMB-001.
Related
- Sector hub: All tracked pharma companies